Evaluating Impurities in Drugs (Part II of III) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluating Impurities in Drugs (Part II of III)
In Part II of a three-part article, the authors examine impurities from chiral molecules, polymorphic contaminants, and genotoxic impurities.


Pharmaceutical Technology
Volume 36, Issue 3, pp. 58-72

60. D.P. Kjell et al., Org. Proc. Res. Dev. 9 (6), 738–742, 2005.

61. K. Kassahun et al., Drug Metab. Dispos. 25 (1), 81–93 (1997).

62. K. Kassahun et al., Drug Metab. Dispos. 26 (9), 848–855 (1998).

63. E. Mattiuz et al., Drug Metab. Dispos. 25 (1), 573–583(1997).

64. M. Lalitha Devi et al., J. Pharm. Biomed. Anal. 50 (5), 710–717 (2009).

65. Y. Yoshida et al., Arzneimittelforschung 43 (5), 601–606 (1993).

66. J. Sunderlanda et al., J. Antimicrob. Chemother. 47 (3), 271–275 (2001).

67. A. V. Polishchuk et al., High Energy Chemistry 42 (6), 459–463 (2008).

68. W. Gau, et al., Arzneimittel Forschung 36 (10), 1545–1549 (1986).

69. P. Mojaverian et al., J. Pharm. Biomed. Anal. 16 (3), 439–445 (1997).

70. A. Taicheng et al., Applied Catalysis B: Environmental 94 (3–4), 288–294, 2010.

71. M. Mella et al., Helvetica Chimica Acta 84 (8), 2508–2519 (2001).

72. K.A. Thabaj et al., Polyhedron 26 (17), 4877–4885 (2007).

73. T.G. Vasconcelos et al., Chemosphere 76 (4), 487–493 (2009).

74. K. Torniainen et al., J. Pharm. Biomed. Anal. 15 (7), 887–894 (1997).

75. K. Tovarna Zdravil, "Process for Preparing Purified Ciprofloxacin," WO 2005/075430, Aug. 2005.

76. R. J. Islam M et al., J. Pharm. Sci. 90 (5), 541–544 (2001).

77. H.V Hogerzeil et al., British Medical Journal 304, 210–214 (1992).

78. R. J. Bhuiyan K et al., Indian Drugs 34 (11), 634-636 (1997).

79. EMA, Guideline on the Limits of Genotoxic Impurities (London, June, 2006).

80. B.N. Ames and L.S. Gold, Proc. Nat. Acad. Sci. USA 87 (19), 7772–7776 (1990).

81. B.N. Ames and L.S. Gold, Proc. Nat. Acad. Sci. USA 87 (19), 7777- 7781 (1990).

82. M.A. Cheeseman et al., Food Chain Toxicol. 37, 387–412 (1999).

83. D.A. Pierson et al., Org. Proc. Res. Dev. 13 (2), 285–291 (2009).

84. D.P. Elder. et al., J. Pharm. Biomed. Anal. 48 (3), 497–507 (2008).

85. D.P. Elder. et al., J. Pharm. Biomed. Anal. 46 (1), 1–8 (2008).

86. D.P. Elder. et al., J. Pharm. Sci. 99 (7,) 2948-2961 (2010).

87. G.E. Taylor. et al., J. Chromatogr A 1119 (1–2), 231–237 (2006).

88. K. Ramakrishna. et al., J. Pharm. Biomed. Anal. 46 (4), 780–783 (2008).

89. N.V.V.S.S. Raman. et al., J. Pharm. Biomed. Anal. 48 (1), 227–230 (2008).

90. J. G. Slatter et al., Drug Metab. Dispos. 29 (8), 1136–1145 (2001).

91. N. Plock et al., Drug Metab. Dispos. l35 (10), 1816–1823 (2007).

92. Wynalda et al., Drug Metab. Dispos. 28 (9), 1014–1017 ( 2000).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here